Adocia Operating Income 2016-2020 | ADOCY

Adocia operating income from 2016 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Adocia Annual Operating Income
(Millions of US $)
2020 $-24
2019 $-25
2018 $10
2017 $-9
2016 $-9
2015 $11
2014 $
2013 $
Adocia Quarterly Operating Income
(Millions of US $)
2020-12-31
2020-06-30
2019-12-31
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2015-12-31
2015-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.083B $0.001B
Adocia SAS is a biotechnology company which is engaged in the development of insulin therapy. The Company develops a BioChaperone platform used for therapeutic protein delivery in regenerative medicine and chronic disease. Adocia SAS is based in Lyon, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29